Application of fragment screening and fragment linking to the discovery of novel thrombin inhibitors

被引:114
作者
Howard, N
Abell, C
Blakemore, W
Chessari, G
Congreve, M
Howard, S
Jhoti, H
Murray, CW
Seavers, LCA
van Montfort, RLM
机构
[1] Astex Therapeut, Cambridge CB4 0QA, England
[2] Univ Cambridge, Chem Lab, Cambridge CB2 1EW, England
关键词
D O I
10.1021/jm050850v
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The screening of fragments is an alternative approach to high-throughput screening for the identification of leads for therapeutic targets. Fragment hits have been discovered using X-ray crystallographic screening of protein crystals of the serine protease enzyme thrombin. The fragment library was designed to avoid any well-precedented, strongly basic functionality. Screening hits included a novel ligand (3), which binds exclusively to the S2-S4 pocket, in addition to smaller fragments which bind to the S1 pocket. The structure of these protein-ligand complexes are presented. A chemistry strategy to link two such fragments together and to synthesize larger drug-sized compounds resulted in the efficient identification of hybrid inhibitors with nanomolar potency (e.g., 7, IC50 = 3.7 nM). These potent ligands occupy the same area of the active site as previously described peptidic inhibitors, while having very different chemical architecture.
引用
收藏
页码:1346 / 1355
页数:10
相关论文
共 60 条
[1]   INHIBITION OF HUMAN ALPHA-THROMBIN, BETA-THROMBIN AND GAMMA-THROMBIN BY MONO-BENZAMIDINE, BIS-BENZAMIDINE, TRIS-BENZAMIDINE AND TETRA-BENZAMIDINE STRUCTURES - THERMODYNAMIC STUDY [J].
ASCENZI, P ;
FRUTTERO, R ;
AMICONI, G ;
PUGLIESE, L ;
BOLOGNESI, M ;
COLETTA, M ;
ONESTI, S ;
GUARNERI, M ;
MENEGATTI, E .
JOURNAL OF ENZYME INHIBITION, 1992, 6 (02) :131-139
[2]   THE CCP4 SUITE - PROGRAMS FOR PROTEIN CRYSTALLOGRAPHY [J].
BAILEY, S .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1994, 50 :760-763
[3]   AMINODIOL HIV PROTEASE INHIBITORS .1. DESIGN, SYNTHESIS, AND PRELIMINARY SAR [J].
BARRISH, JC ;
GORDON, E ;
ALAM, M ;
LIN, PF ;
BISACCHI, GS ;
CHEN, P ;
CHENG, PTW ;
FRITZ, AW ;
GREYTOK, JA ;
HERMSMEIER, MA ;
HUMPHREYS, WG ;
LIS, KA ;
MARELLA, MA ;
MERCHANT, Z ;
MITT, T ;
MORRISON, RA ;
OBERMEIER, MT ;
PLUSCEC, J ;
SKOOG, M ;
SLUSARCHYK, WA ;
SPERGEL, SH ;
STEVENSON, JM ;
SUN, CQ ;
SUNDEEN, JE ;
TAUNK, P ;
TINO, JA ;
WARRACK, BM ;
COLONNO, RJ ;
ZAHLER, R .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (12) :1758-1768
[4]  
Baxter CA, 1998, PROTEINS, V33, P367, DOI 10.1002/(SICI)1097-0134(19981115)33:3<367::AID-PROT6>3.0.CO
[5]  
2-W
[6]   High-throughput X-ray crystallography for drug discovery [J].
Blundell, TL ;
Abell, C ;
Cleasby, A ;
Hartshorn, MJ ;
Tickle, IJ ;
Parasini, E ;
Jhoti, H .
DRUG DESIGN: CUTTING EDGE APPROACHES, 2002, (279) :53-59
[7]  
BODE W, 2005, J THROMB HAEMOSTASIS
[8]   Modulation of flavin recognition and redox properties through donor atom-π interactions [J].
Breinlinger, EC ;
Keenan, CJ ;
Rotello, VM .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1998, 120 (34) :8606-8609
[9]   Structure-based screening of low-affinity compounds [J].
Carr, R ;
Jhoti, H .
DRUG DISCOVERY TODAY, 2002, 7 (09) :522-527
[10]   Fragment-based lead discovery: leads by design [J].
Carr, RAE ;
Congreve, M ;
Murray, CW ;
Rees, DC .
DRUG DISCOVERY TODAY, 2005, 10 (14) :987-992